Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PolandBack to Poland

Clinical trials in Warsaw – page 17

1 804 clinical trials in Warsaw, Poland across 33 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Warsaw at a glance
1 804
clinical trials
  • Research sites33
Type of trial
Recruitment status
Quick filters

1 804 trials in Warsaw

Open in trial search

Metabolic dysfunction-associated steatohepatitis

Recruiting

A Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:Glaxosmithkline Research & Development Limited

Non-small cell lung cancer

Recruiting

Study of MK-1084 plus durvalumab versus placebo plus durvalumab in patients with locally advanced KRAS G12C‑mutant non‑small cell lung cancer after chemoradiotherapy

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Merck Sharp & Dohme LLC

Colitis ulcerative+2

Recruiting

Study of ly4395089 and mirikizumab in adults with moderately to severely active Crohn’s disease

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Mirikizumab
  • Sponsor:Eli Lilly & Co.

Follicular lymphoma

Recruiting

Study of MK-1045 plus rituximab in patients with newly diagnosed follicular lymphoma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Merck Sharp & Dohme LLC

Metabolic dysfunction-associated steatohepatitis

Recruiting

Safety and Efficacy of Efimosfermin Alfa in Participants with Biopsy‑Confirmed F2‑ or F3‑Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:Glaxosmithkline Research & Development Limited

Small cell lung cancer extensive stage

Recruiting

Study of MK-6070 drug combination in first-line extensive-stage small cell lung cancer patients

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Atezolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Iron deficiency

Recruiting

Effect of Ferric Carboxymaltose, Ferrous Sulfate, and Sodium Chloride vs Placebo on Physical Performance in Frail Elderly with Iron Deficiency and Cardiovascular Disease

Registered drug
Countries:PolandPoland
  • Participants:65+ years
  • Substances:Sodium Chloride
  • Sponsor:Wroclaw Medical University

Age-related macular degeneration

Recruiting

Randomized Study of Intravitreal mk-8748 Compared with Aflibercept in Patients with Neovascular Age‑Related Macular Degeneration

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Eyebiotech Limited

Mantle cell lymphoma

Recruiting

Phase 3 Study of Orelabrutinib with Rituximab and Bendamustine vs. Rituximab and Bendamustine in Treatment‑Naïve Mantle Cell Lymphoma Patients

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab

Factor VIII deficiency

Recruiting

Evaluation of NXT007 versus Emicizumab Prophylaxis in Patients with Hemophilia A

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Emicizumab
  • Sponsor:F. Hoffmann-La Roche AG

Factor VIII deficiency

Recruiting

A Phase III study of NXT007 compared with simoctocog alfa prophylaxis in patients with Hemophilia A without inhibitors

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ro7589655
  • Sponsor:F. Hoffmann-La Roche AG

Hodgkin's disease

Recruiting

Study of nivolumab plus drug combination versus standard first-line therapy in patients with advanced Hodgkin lymphoma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Brentuximab Vedotin

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Warsaw

What the registry says about research in the country

01 Respiratory Disease Research

Innovative trials focusing on respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) prevention in older adults. Studies include evaluation of novel vaccine formulations and immune responses in various age groups.

  • RSV Prevention Studies
  • Influenza Vaccine Research
  • Respiratory Infection Management

Particular emphasis on vaccine development for adults aged 60 and older.

02 Immunology Studies

Comprehensive research on meningococcal vaccines across different age groups, from infants to toddlers. Studies evaluate safety profiles and immune responses to various vaccine formulations.

  • Pediatric Vaccine Development
  • Immunogenicity Assessment
  • Vaccine Safety Monitoring

Focus on preventive healthcare through advanced vaccination strategies.

03 Dermatology Research

Studies investigating treatments for psoriasis and psoriatic arthritis, including novel biological therapies and their mechanisms of action.

  • Plaque Psoriasis Treatment
  • Biomarker Analysis
  • Combined Therapy Approaches

Emphasis on moderate to severe cases requiring advanced therapeutic interventions.

04 Oncology Studies

Clinical research focusing on bladder cancer and innovative combination therapies. Studies evaluate treatment efficacy in early-stage non-muscle invasive cases.

  • Immunotherapy Research
  • Cancer Treatment Combinations
  • Disease-Free Survival Analysis

Integration of targeted therapies with standard treatments.

Back to PolandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.